公开(公告)号：US08288509B2

公开(公告)日：2012-10-16

申请号：US12386974

申请日：2009-04-24

申请人： Masaji Okada ,  Yasushi Takamori ,  Kazuyuki Ogawa ,  Kinya Nagata

发明人： Masaji Okada ,  Yasushi Takamori ,  Kazuyuki Ogawa ,  Kinya Nagata

IPC分类号： A61K39/00 ,  A61K39/38 ,  A61K38/00 ,  C07K16/00 ,  C07K17/00 ,  C07K5/00 ,  C07K7/00 ,  C07K14/00

CPC分类号： A61K38/20 ,  A61K38/164 ,  A61K38/1709 ,  A61K38/1729 ,  A61K38/204 ,  A61K38/208 ,  A61K39/04 ,  A61K2300/00

摘要： (Problems)To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same.(Means for Solving Problems)The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.

摘要翻译： （问题）为了提供包含颗粒溶素作为活性成分的感染治疗剂，其副作用小，无细胞毒性，细菌几乎不能获得抗性，以及使用该治疗剂的治疗方法。 （解决问题的手段）本发明提供一种感染治疗剂，其包含15K颗粒溶素，15K颗粒溶素和15K颗粒溶素在体内表达载体的组合，15K颗粒溶素与至少一种选自IL- 6，IL-23或IL-27，15K颗粒溶素在体内表达载体和选自IL-6，IL-23或IL-27中的至少一种白介素或15K颗粒溶素的体内表达载体和HSP65DNA的组合的组合 和IL-12DNA体内表达载体，其对细菌的杀伤作用增强，副作用较小，细菌几乎不能获得抗性，以及使用其的处理方法。

公开(公告)号：US20100015643A1

公开(公告)日：2010-01-21

申请号：US12301535

申请日：2007-05-21

申请人： Chuwa Tei ,  Kouji Orihara ,  Kinya Nagata ,  Ryutaro Oba ,  Hiroyuki Hirai

发明人： Chuwa Tei ,  Kouji Orihara ,  Kinya Nagata ,  Ryutaro Oba ,  Hiroyuki Hirai

IPC分类号： G01N33/567

CPC分类号： G01N33/5091 ,  G01N33/5094 ,  G01N33/6893 ,  G01N2800/26

摘要： There is provided a method of quantitative determination using a flow cytometer, with which quantitative determination of cell surface protein can be effected more accurately than with current methods. The inventors have achieved the present invention by providing a method of quantitative determination of sites, per cell of a test sample, at which an antibody is bound to an antigen protein (sites/cell), characterized by preparing a calibration curve on the basis of fluorescent intensities obtained through measuring with a flow cytometer the amount of labeled antibodies against antigen protein which are bound to two or more groups of beads carrying known and different amounts of the antigen protein, and numeric values of the known amounts of the antigen protein, and further by measuring, with the flow cytometer, labeled antibodies against antigen protein after they have been reacted with test cells derived from a blood sample of a test subject, whereby digitalization is effected through comparison and conversion between the calibration curve and a fluorescence intensity obtained.

摘要翻译： 提供了一种使用流式细胞仪进行定量测定的方法，可以比目前的方法更准确地进行细胞表面蛋白的定量测定。 发明人通过提供定量测定抗体与抗原蛋白（位点/细胞）结合的测试样品的每个细胞的位点的方法来实现本发明，其特征在于基于以下方式制备校准曲线 通过用流式细胞仪测量获得的荧光强度，结合到携带已知和不同量的抗原蛋白的两个或更多个珠粒组的抗原蛋白的标记抗体的量，以及已知量的抗原蛋白的数值，以及 进一步通过用流式细胞仪测量抗原蛋白的抗体，在与测试受试者的血液样本的测试细胞反应之后，通过比较和转换校正曲线和获得的荧光强度来进行数字化。

公开(公告)号：US20090274651A1

公开(公告)日：2009-11-05

申请号：US12386974

申请日：2009-04-24

申请人： Masaji Okada ,  Yasushi Takamori ,  Kazuyuki Ogawa ,  Kinya Nagata

发明人： Masaji Okada ,  Yasushi Takamori ,  Kazuyuki Ogawa ,  Kinya Nagata

IPC分类号： A61K38/20 ,  C07K14/47 ,  A61K38/16 ,  A61K31/711 ,  A61P31/06

CPC分类号： A61K38/20 ,  A61K38/164 ,  A61K38/1709 ,  A61K38/1729 ,  A61K38/204 ,  A61K38/208 ,  A61K39/04 ,  A61K2300/00

摘要： (Problems) To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same. (Means for Solving Problems) The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.

摘要翻译： （问题）为了提供包含颗粒溶素作为活性成分的感染治疗剂，其副作用小，无细胞毒性，细菌几乎不能获得抗性，以及使用该治疗剂的治疗方法。 （解决问题的手段）本发明提供一种感染治疗剂，其包含15K颗粒溶素，15K颗粒溶素和15K颗粒溶素在体内表达载体的组合，15K颗粒溶素与至少一种选自IL- 6，IL-23或IL-27，15K颗粒溶素在体内表达载体和选自IL-6，IL-23或IL-27中的至少一种白介素或15K颗粒溶素的体内表达载体和HSP65DNA的组合的组合 和IL-12DNA体内表达载体，其对细菌的杀伤作用增强，副作用较小，细菌几乎不能获得抗性，以及使用其的处理方法。

公开(公告)号：US6166186A

公开(公告)日：2000-12-26

申请号：US480784

申请日：2000-01-10

申请人： Kazuyuki Ogawa ,  Kazuya Tanaka ,  Kinya Nagata ,  Syoichi Takano

发明人： Kazuyuki Ogawa ,  Kazuya Tanaka ,  Kinya Nagata ,  Syoichi Takano

IPC分类号： A61K38/00 ,  C07K14/47 ,  C07K14/705 ,  C07K16/28 ,  C12N15/12 ,  C12P21/08 ,  C12N5/12 ,  C07K16/44

CPC分类号： C07K16/28 ,  A61K38/00 ,  C07K14/47 ,  C07K14/705 ,  C07K14/70503

摘要： The present specification provides a means for specifying the condition and type of immune-related diseases on the basis of knowledge about the polarization of the distribution of helper T-cell subsets Th1 and Th2. More specifically, the gene (B19), specific only to the human Th2, is prepared by a subtraction method. A human-Th2-specific protein which the gene encodes is produced by recombinant methods, and a monoclonal antibody against the Th2-specific protein and a hybridoma which produces the monoclonal antibody is provided.

摘要翻译： 本说明书提供了一种用于根据关于辅助T细胞子集Th1和Th2分布的极化的知识来指定免疫相关疾病的病症和类型的手段。 更具体地，通过减法法制备仅对人Th2特异的基因（B19）。 通过重组方法产生基因编码的人Th2特异性蛋白质，提供抗Th2特异性蛋白质的单克隆抗体和产生单克隆抗体的杂交瘤。

公开(公告)号：US6040426A

公开(公告)日：2000-03-21

申请号：US981825

申请日：1998-05-11

申请人： Kazuyuki Ogawa ,  Kazuya Tanaka ,  Kinya Nagata ,  Syoichi Takano

发明人： Kazuyuki Ogawa ,  Kazuya Tanaka ,  Kinya Nagata ,  Syoichi Takano

IPC分类号： A61K38/00 ,  C07K14/47 ,  C07K14/705 ,  C07K16/28 ,  C12N15/12 ,  C12P21/08 ,  C07K14/435

CPC分类号： C07K16/28 ,  C07K14/47 ,  C07K14/705 ,  C07K14/70503 ,  A61K38/00

摘要： The present invention provides for specifying the condition and type of immune-related diseases on the basis of the knowledge about the polarization of the distribution of helper T-cell subsets Th1 and Th2. More sepcifically, in this invention, the gene (B19) specific only the human Th2 is prepared and specified by a subtraction method, and a recombinant vector into which the gene is incorporated, a transformant transformed by the recombinant vector, a human-Th2-specific protein which the gene encodes and which derives from the transformant, and a monoclonal antibody against the Th2-specific protein are produced and the gene, protein, antibody, etc. are used as the means for specifying or correcting the polarization of the distribution of Th1 and Th2 to solve the above object.

摘要翻译： PCT No.PCT / JP97 / 01906 Sec。 371日期：1998年5月11日 102（e）日期1998年5月11日PCT提交1997年6月5日PCT公布。 公开号WO97 / 46677 日期1997年12月11日本发明基于关于辅助T细胞亚群Th1和Th2的分布的极化的知识，提供免疫相关疾病的病症和类型的指定。 更具体地说，在本发明中，通过减法法制备和规定了仅具有人Th2的基因（B19），并且其中掺入了该基因的重组载体，由重组载体转化的转化体，人Th2- 产生基因编码并衍生自转化体的特异性蛋白质，并且产生针对Th2特异性蛋白质的单克隆抗体，并且使用基因，蛋白质，抗体等作为用于指定或校正分布的极化的手段 Th1和Th2解决上述目的。

公开(公告)号：US20050239699A1

公开(公告)日：2005-10-27

申请号：US10921091

申请日：2004-08-17

申请人： Masaji Okada ,  Yasushi Takamori ,  Kazuyuki Ogawa ,  Kinya Nagata

发明人： Masaji Okada ,  Yasushi Takamori ,  Kazuyuki Ogawa ,  Kinya Nagata

IPC分类号： C12N15/09 ,  A61K38/00 ,  A61K38/16 ,  A61K38/17 ,  A61K48/00 ,  A61P31/04 ,  A61P31/06 ,  C07K14/47

CPC分类号： A61K38/16 ,  A61K38/1709

摘要： According to the present invention, there is provided a remedy for infections containing 15K granulysin as an active ingredient, which has no perceived side effect, and is effective.

摘要翻译： 根据本发明，提供了含有15K颗粒溶素作为活性成分的感染的补救剂，其没有察觉到副作用，并且是有效的。

公开(公告)号：US06884593B1

公开(公告)日：2005-04-26

申请号：US10069148

申请日：2000-08-22

申请人： Hiroyuki Hirai ,  Kazuyuki Ogawa ,  Kinya Nagata ,  Syoichi Takano

发明人： Hiroyuki Hirai ,  Kazuyuki Ogawa ,  Kinya Nagata ,  Syoichi Takano

IPC分类号： G01N33/88 ,  G01N33/53 ,  G01N33/567

CPC分类号： G01N33/88 ,  G01N2500/04

摘要： An object of the present invention is to provide a method of identifying a substance which acts on a newly found second human prostaglandin D2 receptor subtype that differs from the DP receptor, and is useful for treating or preventing various diseases. In order to attain the object, the present invention provides a method of identifying properties of a test substance with respect to a human prostaglandin D receptor, by establishing correlation between the effect of a test substance on human CRTH2 with the effect of the test substance on the human prostaglandin D receptor.

摘要翻译： 本发明的目的是提供一种鉴定作用于新发现的与DP受体不同的第二人前列腺素D 2受体亚型的物质的方法，并且可用于治疗或预防各种 疾病 为了达到上述目的，本发明提供了一种鉴定被测物质相对于人前列腺素D受体的性质的方法，其特征在于，测试物质对人CRTH2的作用与受检物质对 人类前列腺素D受体。

公开(公告)号：US20130011366A1

公开(公告)日：2013-01-10

申请号：US13604645

申请日：2012-09-06

申请人： Masaji Okada ,  Yasushi Takamori ,  Kazuyuki Ogawa ,  Kinya Nagata

发明人： Masaji Okada ,  Yasushi Takamori ,  Kazuyuki Ogawa ,  Kinya Nagata

IPC分类号： A61K38/17 ,  A61P31/06 ,  C12N15/63 ,  A61K38/20 ,  A61K48/00

CPC分类号： A61K38/20 ,  A61K38/164 ,  A61K38/1709 ,  A61K38/1729 ,  A61K38/204 ,  A61K38/208 ,  A61K39/04 ,  A61K2300/00

摘要： (Problems)To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same.(Means for solving problems)The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.

摘要翻译： （问题）为了提供包含颗粒溶素作为活性成分的感染治疗剂，其副作用小，无细胞毒性，细菌几乎不能获得抗性，以及使用该治疗剂的治疗方法。 （解决问题的手段）本发明提供一种感染用治疗剂，其包含作为活性成分的15K颗粒溶素，15K颗粒溶素和15K颗粒溶素在体内表达载体的组合，15K颗粒溶素与至少一种选自IL- 6，IL-23或IL-27，15K颗粒溶素在体内表达载体和选自IL-6，IL-23或IL-27中的至少一种白介素或15K颗粒溶素的体内表达载体和HSP65DNA的组合的组合 和IL-12DNA体内表达载体，其对细菌的杀伤作用增强，副作用较小，细菌几乎不能获得抗性，以及使用其的处理方法。

公开(公告)号：US20050144662A1

公开(公告)日：2005-06-30

申请号：US10942954

申请日：2004-09-17

申请人： Masataka Nakamura ,  Kazuo Sugamura ,  Shoichi Takano ,  Kinya Nagata ,  Hiroyuki Hirai

发明人： Masataka Nakamura ,  Kazuo Sugamura ,  Shoichi Takano ,  Kinya Nagata ,  Hiroyuki Hirai

IPC分类号： A01K67/027 ,  C07K14/705 ,  C12N15/09 ,  C12N15/85 ,  G01N33/15 ,  G01N33/50

CPC分类号： C12N15/8509 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  C07K14/705

摘要： A knockout mouse whose genome includes an inactivated CRTH2 gene. The knockout mouse is obtained by subjecting to a serial passage a chimeric mouse originating from an early embryo to which a CRTH2-gene-knocked-out mouse embryonic stem cell has been introduced. Also disclosed is a detection method which includes employing, as an index, pathological condition of the knockout mouse to which the test substance has been administered, to thereby detect, in vivo, characteristics of a test substance in relation to CRTH2, or functions of CRTH2 in the living body.

摘要翻译： 基因组的敲除小鼠，其包含失活的CRTH2基因。 敲除小鼠通过连续通过源自已经引入了CRTH2基因敲除的小鼠胚胎干细胞的早期胚胎的嵌合小鼠获得。 还公开了一种检测方法，其包括使用已经施用受检物质的敲除小鼠的病理状态作为指标，从而检测体内与CRTH2相关的测试物质的特征，或CRTH2的功能 在活体内。

公开(公告)号：US5962319A

公开(公告)日：1999-10-05

申请号：US869793

申请日：1997-06-05

申请人： Kazuyuki Ogawa ,  Kazuya Tanaka ,  Kinya Nagata ,  Shoichi Takano

发明人： Kazuyuki Ogawa ,  Kazuya Tanaka ,  Kinya Nagata ,  Shoichi Takano

IPC分类号： C07K14/47 ,  C12N15/12 ,  C12N5/10

CPC分类号： C07K14/47

摘要： An element for specifying the condition and type of immune-related diseases on the basis of the knowledge about the polarization of distribution of Th1/Th2 subsets of helper T cells. The element for specifying or correcting the polarization of the Th1/Th2 subsets is implemented by use of a recombinant vector, a transformant, a human-Th1-specific protein, and an antibody which uses the human-Th1-specific protein as an antigen. A human-Th1-specific gene is prepared and specified by a subtraction technique and is incorporated into the recombinant vector. The transformant is formed by transforming the recombinant vector. The Th1-specific protein is encoded by the gene derived from the transformant.

摘要翻译： 根据关于辅助T细胞Th1 / Th2亚型分布极化的知识，指定免疫相关疾病的病情和类型的要素。 通过使用重组载体，转化体，人Th1特异性蛋白质和使用人Th1特异性蛋白质作为抗原的抗体来实现用于指定或校正Th1 / Th2子集的极化的元件。 制备人Th1特异性基因并通过减法技术规定并且并入重组载体中。 通过转化重组载体形成转化体。 Th1特异性蛋白质由转化体衍生的基因编码。